Transitional cell carcinoma

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

Researchers are testing whether a chemotherapy combination called gemcitabine and carboplatin can help people with advanced urothelial cancer whose disease has worsened after treatment with enfortumab vedotin and pembrolizumab. The trial enrolls about 55 participants who receive …

This study tests whether giving two drugs (enfortumab vedotin and pembrolizumab) before bladder cancer surgery can eliminate cancer in the lymph nodes and shrink tumors. About 23 adults with advanced bladder cancer that has spread to lymph nodes will receive the combination befor…

This early-phase trial is testing an experimental drug called BMS-986504 alongside standard cancer treatments in 60 people with advanced cancers that have lost a gene called MTAP. The cancers include mesothelioma, stomach/esophageal cancer, and bladder cancer. The main goal is to…

This phase II trial is testing whether a combination of three drugs—cabozantinib, nivolumab, and ipilimumab—can shrink or slow the growth of rare genitourinary cancers that have spread. About 314 adults with these uncommon tumors will receive the drugs. The goal is to see if the …

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This named patient program gives doctors controlled, pre-approval access to a mitomycin gel called JELMYTO for specific patients with cancer of the renal pelvis or ureter. It is for people in select countries where the treatment is not yet approved and who have exhausted other op…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This program provides early access to cretostimogene grenadenorepvec, a virus-based therapy, for patients with non-muscle invasive bladder cancer that has not responded to standard BCG treatment. Eligible participants have a specific type of bladder cancer (CIS with or without hi…

Researchers are testing whether adding ivonescimab to enfortumab vedotin works better than adding pembrolizumab to enfortumab vedotin in people with locally advanced or metastatic urothelial cancer who have not yet received systemic treatment. The trial enrolls about 800 adults w…

This study tests whether two drugs, enfortumab vedotin and pembrolizumab, can control muscle-invasive bladder cancer without needing to remove the bladder. About 390 adults whose cancer hasn't spread outside the bladder will receive either the drug combo or standard chemoradiatio…

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …

This Phase 1 trial tests a new drug called BL-M07D1 in 280 adults with advanced HER2-positive cancers, including breast, lung, and stomach cancers. The study aims to find safe doses and check for early signs of tumor shrinkage. Participants must have tried at least two prior trea…

This study tests a decision tool to help select women with bladder cancer who can safely keep their reproductive organs during bladder removal surgery. Currently, standard surgery removes the bladder, uterus, ovaries, and part of the vagina, which can harm sexual health, mental h…

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study tests a new gel-like drug, UGN-104, placed directly into the upper urinary tract to treat low-grade cancer. About 70 adults with small tumors will receive the treatment to see if it can completely eliminate visible cancer. The goal is to control the disease and avoid m…

This early-phase study tests a new drug, ASP2998, that targets a protein called TROP2 found on many solid tumors. The drug is given alone or with standard treatments like pembrolizumab or carboplatin. The main goals are to check safety and find the right dose. About 428 adults wi…

This early-phase trial is testing whether adding an experimental drug called emavusertib (CA-4948) to the immunotherapy pembrolizumab can help patients with advanced urothelial cancer whose tumors have become resistant to PD-1/PD-L1 blockers. The study will enroll 27 adults and f…

This phase III trial tests whether combining two drugs—pembrolizumab (an immunotherapy) and sacituzumab govitecan (a targeted chemotherapy)—works better than standard chemotherapy for people with advanced bladder cancer that has stopped responding to initial immunotherapy. About …

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests whether adding a new targeted medicine (vepugratinib) to two standard cancer drugs can help people with advanced bladder cancer that has a specific genetic change (FGFR3). About 450 adults whose cancer has spread or cannot be removed by surgery will take part. Th…

This study is checking the safety of enfortumab vedotin in 100 Indian adults whose bladder cancer has spread or come back after other treatments. Participants receive the drug through an IV every 4 weeks. The main goal is to track side effects, but researchers will also see if th…

This study is for people with advanced bladder cancer that has gotten worse after standard treatment. It tests a new drug combination (datopotamab deruxtecan plus chemotherapy) against another chemotherapy combo. The goal is to see if the new combo can shrink tumors or slow the c…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This early-stage trial is testing a new oral drug called DCC-2812 in 60 people with advanced kidney, bladder, or prostate cancers that have spread. The main goals are to check safety and find the right dose, while also looking for signs that the drug can shrink tumors. It is a fi…

This study tests a new medicine, PF-08634404, in adults with advanced bladder cancer that has spread. Some participants receive the drug alone, while others get it combined with another cancer drug. The goal is to check safety, how well it works, and how it affects the body. Abou…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This phase 3 trial is testing whether a combination of two drugs, SHR-A2102 and adebrelimab, works better than standard chemotherapy for people with advanced bladder cancer that has not been treated before. About 462 participants will be randomly assigned to receive either the ne…

This phase 2 trial tests whether the drug sacituzumab govitecan, alone or combined with atezolizumab, can shrink rare tumors of the kidney, bladder, ureters, or penis. About 60 adults with specific rare cancer types will receive the drugs intravenously in 21-day cycles. The study…

This study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…

This study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This Phase 1 trial tests whether HLX18, a biosimilar of the cancer drug OPDIVO, works similarly in people with esophageal, melanoma, or bladder cancer after their tumors have been surgically removed. About 174 participants will receive either HLX18 or OPDIVO to compare how the dr…

This phase II trial is testing whether combining an experimental drug called BL-B01D1 with a PD-1 inhibitor can shrink tumors in people with advanced or metastatic urothelial carcinoma (a type of bladder cancer) who have not had prior systemic therapy. The study will measure how …

This phase 3 trial is testing whether a combination of two drugs—datopotamab deruxtecan and rilvegostomig—given after surgery can prevent cancer recurrence in people with high-risk muscle invasive bladder cancer. Participants who have had their tumor completely removed will recei…

This phase 2 trial is testing whether the drug disitamab vedotin, alone or with pembrolizumab, can shrink tumors in people with advanced bladder cancer that has spread or cannot be removed. The study includes 372 participants whose cancer cells have a protein called HER2. Researc…

This phase 2 trial tests whether adding one of four different drugs to a standard immunotherapy combination can help people with HER2-positive muscle-invasive bladder cancer avoid bladder removal. Participants receive disitamab vedotin and toripalimab plus a sensitizing agent, th…

This trial tests whether giving two drugs—enfortumab vedotin and pembrolizumab—before surgery can improve outcomes for people with upper tract urothelial cancer (a type of bladder cancer in the kidney or ureter). Participants receive the drugs intravenously, then undergo surgery …

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …

This expanded access program provides vepugratinib, an oral drug, to people with metastatic urothelial carcinoma or other solid tumors that have a specific FGFR3 genetic change. Participants must have exhausted other approved treatments, including erdafitinib for bladder cancer, …

This study tests whether adding targeted radiation or heat-based ablation to ongoing drug therapy can control genitourinary cancers (prostate, bladder, or kidney) that have started growing in only a few new areas. Participants continue their current systemic treatment while recei…

This study tests whether a new combination of drugs (enfortumab vedotin plus toripalimab) works better than standard chemotherapy before bladder cancer surgery. About 58 adults with high-risk muscle-invasive bladder cancer will be randomly assigned to one of the two treatments fo…

This early-phase study tests a new radioactive drug (BRP-020063) in 10 people with advanced solid tumors that have spread. The drug is used first for imaging to find tumors, then a low dose is given to see if it's safe and how it travels in the body. The goal is to gather informa…

This early-phase trial is testing a new drug called zilovertamab vedotin, alone or with the immunotherapy pembrolizumab, in 48 people with advanced bladder cancer that no longer responds to standard PD-1/L1 inhibitors. The study aims to see if the treatment is safe and can shrink…

This early-stage trial is testing a new mRNA-based drug called MT-304, alone or with the immunotherapy nivolumab, in adults with advanced HER2-expressing solid tumors. The main goals are to check safety, find the right dose, and get a first look at whether it shrinks tumors. Abou…

This early-phase trial tests AVA6000, a chemotherapy drug that is designed to activate only in tumors, potentially reducing side effects. About 158 adults with advanced solid tumors (like breast, ovarian, or salivary gland cancer) will receive the drug intravenously. The main goa…

This study is for people with bladder cancer that has spread to a small number of other body parts (up to 3 spots). It compares standard treatment (chemotherapy or immunotherapy) alone versus standard treatment plus a precise, high-dose radiation therapy called SBRT. The goal is …

This phase 2 trial tests whether combining two drugs—sacituzumab govitecan and nivolumab—after surgery can keep high-risk bladder cancer from coming back. About 23 adults who had their bladder or part of their urinary tract removed will receive the drugs intravenously. The main g…

This phase II trial is testing a drug called trastuzumab rezetecan, either alone or with an immunotherapy drug called adebrelimab, in people with advanced bladder cancer that has a protein called HER2. The study aims to see if these treatments can shrink tumors or slow the cancer…

This early-phase trial is testing whether combining two drugs—cabozantinib and enfortumab vedotin—can safely treat advanced bladder cancer that has spread. About 32 adults whose cancer worsened after standard treatments will receive the combo. The study aims to find the best dose…

This phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in about 508 adults with advanced bladder cancer that has worsened after prior treatments. The goal is to see if the new drug can slow cancer growth or improve survival. Participants will receive ei…

This phase 2 trial is testing whether two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder can treat high-risk bladder cancer that did not respond to standard BCG therapy. About 174 adults will receive weekly treatments for 6 weeks, then monthly for …

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This study tests a combination of three drugs (trastuzumab, serplulimab, and chemotherapy) in 20 adults with advanced bile duct or bladder cancers that have stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and improve survival. Part…

This early-stage study tests a new treatment for people with advanced bladder cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from a healthy donor, designed to target two proteins on cancer cells. Participan…

This study tests whether a maintenance drug (pembrolizumab) can help control advanced bladder cancer after an initial 18-week combination treatment. About 97 people who have not had prior therapy for metastatic disease will participate. The goal is to see if this approach improve…

This study is testing whether people with advanced bladder cancer can switch to a milder treatment after an initial strong combination therapy. Participants first receive two drugs (pembrolizumab and enfortumab vedotin) for 24 weeks. If their cancer is controlled, they then recei…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This study tests whether combining two drugs (9MW2821 and toripalimab) before and after surgery can improve outcomes for people with urothelial cancer (a type of bladder cancer). About 90 adults with non-spread cancer will receive the treatment and be monitored for tumor shrinkag…

This study looks at whether a combination of radiation and immunotherapy works better than standard chemotherapy after surgery for a rare type of kidney cancer called upper tract urothelial carcinoma. About 178 patients with high-risk features will be followed to see which treatm…

This phase 2 trial tests erdafitinib alone or with cetrelimab before surgery in 90 people with muscle-invasive bladder cancer that has specific gene changes (FGFR). Participants cannot take standard cisplatin chemotherapy. The goal is to see if the drugs can eliminate or shrink t…

This early-phase trial tests a new drug called MT-4561 in about 27 people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have no standard options left. The main goals are to find a safe dose and see if the drug can shrink tumors. It is a first-in-human s…

This early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…

This study tests a new drug called Ruvidar, given directly into the bladder, for people with a type of bladder cancer that did not respond to or could not tolerate standard BCG therapy. About 90 adults will receive up to three treatment sessions. The main goal is to see if the dr…

This study is for people with metastatic urothelial cancer (a type of bladder cancer that has spread). It tests two or three drugs together: sacituzumab govitecan, enfortumab vedotin, and pembrolizumab. The goal is to find the safest doses and see how well the combination shrinks…

This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced bladder cancer or other solid tumors that have not responded to standard treatments. The goal is to see if these drugs can shrink tumors or slow disease progression. About 52…

This phase 2 trial is testing whether a combination of two drugs, Talazoparib and Avelumab, can help keep advanced urothelial (bladder) cancer from growing after initial chemotherapy. About 50 adults with platinum-sensitive cancer will receive the drugs as maintenance therapy unt…

This early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…

This study looks at 1,000 adults who have microscopic blood in their urine (microhematuria), which can be a sign of bladder cancer. Currently, many need a cystoscopy—a camera inserted into the bladder—which can be uncomfortable. The study tests whether a urine test called Cxbladd…

This study is testing whether a urine test can accurately detect urothelial carcinoma, a type of cancer that includes bladder cancer. Researchers are comparing the test results to standard tissue biopsies in 800 adults with blood in their urine and suspicious imaging findings. If…

This study is testing a new urine test called UroAmp to see if it can accurately detect bladder cancer and monitor for its return. Researchers will collect urine and tumor samples from 2,500 people being evaluated or treated for bladder cancer or related conditions. The goal is t…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study compares CT and MRI scans to see which more accurately determines if bladder cancer has spread into the muscle layer. About 150 adults with newly diagnosed bladder cancer will receive both scans before standard surgery. The results will be checked against tissue sample…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study is testing whether regular urine tests every 6 months can find bladder cancer earlier in people at high risk, such as smokers over 50 and those with long-term workplace chemical exposure. Researchers will enroll 1,000 participants and track how many cancers are detecte…

This pilot study is testing whether a special PET/CT scan using 68Gallium PSMA can find cancer that has spread in people with metastatic bladder cancer or melanoma. Twenty participants will receive both the standard FDG-PET/CT scan and the new 68Ga PSMA-PET/CT scan within 10 days…

This study tests a new radioactive tracer called 68Ga-N188 that targets a protein called nectin-4, often found on urothelial cancer cells. Researchers will use PET/CT scans to see how well this tracer spots tumors in 20 people with recurrent or advanced bladder cancer. The goal i…

This study is testing a new liquid biopsy that uses blood and urine samples to help diagnose, monitor treatment, and predict recurrence in people with urothelial carcinoma (a type of bladder cancer). Researchers will enroll 300 participants and compare the liquid biopsy results w…

This study is testing whether specially trained dogs can detect bladder cancer by smelling urine samples. Researchers will collect urine from 340 adults scheduled for bladder surgery and see how often the dogs correctly identify cancer. If it works, this could lead to a simple, n…

This study is testing whether a urine test that looks for tumor DNA can find bladder and urinary tract cancers early in people with Lynch syndrome, a genetic condition that raises cancer risk. About 200 participants aged 50–75 will provide urine samples and be followed for one ye…

This study is testing whether a combined blood and urine DNA test can accurately detect muscle-invasive bladder cancer in patients scheduled for bladder removal surgery. Researchers will compare the test results with the actual findings from surgery. The goal is to see if this no…

This study is testing whether a simple urine test that looks for tumor DNA can replace the standard invasive cystoscopy (a camera inserted into the bladder) for diagnosing bladder cancer. Researchers will enroll 3,000 people who have blood in their urine and are scheduled for a c…

This study tests whether wearing a compression stocking on one foot during antibody-drug conjugate (ADC) infusions can prevent peripheral neuropathy (nerve damage causing numbness or pain). Fifty-eight advanced cancer patients will wear a stocking on their left foot only, while t…

This study looks at whether doing simple exercises at home before bladder or upper tract cancer surgery can help patients feel stronger and recover faster. About 128 adults scheduled for surgery will either receive a personalized home exercise plan via a smartphone app or standar…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This early-phase study tests an investigational drug called GB-4362 given alongside standard treatments (enfortumab vedotin and pembrolizumab) for adults with advanced or metastatic urothelial cancer. The goal is to see if GB-4362 can safely neutralize a chemotherapy byproduct th…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…

This study looks at whether placing a small tube (stent) in the urinary tract after bladder removal surgery affects recovery. About 70 adults with bladder or pelvic cancers will be randomly assigned to get a stent or not. The main goal is to see if avoiding stents lowers the risk…

This study is testing whether a blood test can find tiny pieces of tumor DNA in people with muscle-invasive bladder cancer or upper tract urothelial cancer. Researchers will compare DNA from tumor tissue with DNA in blood samples taken during routine care. The goal is to see how …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study is a large registry that will follow nearly 2,000 people with advanced kidney or bladder cancer in Germany. Researchers will collect information on the treatments patients actually receive, how well they work, and patients' quality of life. The goal is to understand re…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study looks at how the drug enfortumab vedotin affects nerves in people with advanced or muscle-invasive bladder cancer. Researchers will use nerve tests and patient surveys to track changes over 9-15 weeks. The goal is to better understand and potentially reduce nerve damag…

This study is for 150 adults having surgery for bladder cancer. Researchers want to see if the amount of fluid absorbed during surgery and changes in DNA in the blood can help predict if the cancer will return or get worse. The goal is to improve how doctors assess risk and plan …

This study is observing 300 adults with kidney, bladder, lung, or liver cancer who are starting immunotherapy (PD-1/PDL-1 inhibitors). Researchers will measure a protein called Galectin-3 in the blood before each treatment to see if its level is linked to how well the therapy wor…

This study collects tumor, blood, urine, and stool samples from 1000 adults with suspected or confirmed bladder cancer. The samples are stored securely for future biological and genetic research. The goal is to build a resource that can help scientists better understand the disea…

This study follows 300 Korean adults with high-grade upper tract urothelial carcinoma (a type of cancer in the kidney or ureter) to monitor for cancer recurrence. Participants will receive standard treatment (chemotherapy before surgery to remove the kidney and ureter) and provid…

This study looks at nerve damage (peripheral neuropathy) in people with advanced bladder cancer who are getting a combination of two drugs, pembrolizumab and enfortumab vedotin, as their first treatment. About 80 participants will be followed for a year to see how often nerve pro…

This study looks at whether a short survey called the Geriatric-8 can help doctors choose the best treatment for older patients with advanced bladder cancer who cannot take the strong chemotherapy drug cisplatin. Researchers will compare quality of life and side effects between t…

This study follows 500 people with genitourinary cancers (like prostate, bladder, or kidney cancer) to see how well recently approved drugs work in everyday Spanish hospitals. Researchers will collect data from patients already taking these medications, without changing their tre…

This study watches how hospitals handle patients admitted with blood in their urine (hematuria). It will track things like how long people stay in the hospital and how quickly they get a diagnosis. The goal is to find the best ways to manage this condition and create guidelines f…

This study looks at how kidney and bladder cancers use nutrients like sugar and fat to grow. Participants receive a harmless nutrient tracer during surgery or biopsy, and researchers collect blood and tissue samples to analyze cancer metabolism. The study does not change standard…

This study looks at why some people with advanced bladder cancer receive older platinum-based chemotherapy instead of a newer, more effective drug combination. Researchers will review the medical records of 50 patients to understand the reasons behind these treatment choices. The…

This study looks at women aged 50 and older who have visible blood in their urine along with a bladder infection. Researchers want to find out if these women really need to undergo invasive tests like cystoscopy and CT scans to check for bladder or kidney cancer. By following 300…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This observational study is collecting blood samples and medical images from 200 people with several types of solid tumors (like lung, head and neck, and esophageal cancers) who are receiving immunotherapy and radiation as part of their standard care. Researchers want to see if c…

This study looks at whether removing lymph nodes during standard kidney-ureter surgery helps people with upper tract urothelial carcinoma. About 94 adults with this rare cancer will be randomly assigned to get either the standard surgery alone or the surgery plus lymph node remov…